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Abstract
Background: Neuroacanthocytosis (NA) denotes a heterogeneous group of diseases that are
characterized by nervous system abnormalities in association with acanthocytosis in the patients'
blood. The 4.1R protein of the erythrocyte membrane is critical for the membrane-associated
cytoskeleton structure and in central neurons it regulates the stabilization of AMPA receptors on
the neuronal surface at the postsynaptic density. We report clinical, biochemical, and genetic
features in four patients from four unrelated families with NA in order to explain the cause of
morphological abnormalities and the relationship with neurodegenerative processes.
Case presentation: All patients were characterised by atypical NA with a novel alteration of the
erythrocyte membrane: a 4.1R protein deficiency. The 4.1R protein content was significantly lower
in patients (3.40 ± 0.42) than in controls (4.41 ± 0.40, P < 0.0001), reflecting weakened interactions
of the cytoskeleton with the membrane. In patients IV:1 (RM23), IV:3 (RM15), and IV:6 (RM16) the
4.1 deficiency seemed to affect the horizontal interactions of spectrin and an impairment of the
dimer self-association into tetramers was detected. In patient IV:1 (RM16) the 4.1 deficiency
seemed to affect the skeletal attachment to membrane and the protein band 3 was partially
reduced.
Conclusion: A decreased expression pattern of the 4.1R protein was observed in the
erythrocytes from patients with atypical NA, which might reflect the expression pattern in the
central nervous system, especially basal ganglia, and might lead to dysfunction of AMPA-mediated
glutamate transmission.
Published: 13 February 2007
BMC Neurology 2007, 7:4 doi:10.1186/1471-2377-7-4
Received: 15 July 2006
Accepted: 13 February 2007
This article is available from: http://www.biomedcentral.com/1471-2377/7/4
© 2007 Orlacchio et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Neurology 2007, 7:4 http://www.biomedcentral.com/1471-2377/7/4Background
Acanthocytosis is found to be associated with at least three
hereditary neurological disorders that are generally
referred to as neuroacanthocytosis (NA): Chorea-acan-
thocytosis (ChAc), Abetalipoproteinaemia, and McLeod
syndrome [1,2]. ChAc is typically an autosomal recessive
condition characterised by chorea, orofaciolingual dyski-
nesia, dysphagia, dysarthria, areflexia, seizures, and
dementia. Abetalipoproteinaemia is also an autosomal
recessive condition characterised by the absence of serum
apoliprotein B resulting in progressive spinocerebellar
ataxia with peripheral neuropathy, chorea, and retinitis
pigmentosa. McLeod syndrome is an X-linked disorder
characterised by the abnormal expression of the Kell
blood group antigen and by elevated serum creatine
kinase levels, myopathy, and chorea [1,2].
Abnormalities of the major integral membrane protein
band 3 have been reported in cases of autosomal recessive
ChAc, although the relationship between this alteration
and the neurodegenerative processes has yet to be deter-
mined [1].
We performed clinical, biochemical, and genetic investi-
gations in four patients with atypical NA associated with a
novel alteration of erythrocyte membrane: that is a defect
of the 4.1R protein. Erythroid 4.1R protein is essential for
maintaining erythrocyte shape and mechanical properties
of the membrane, such as deformability and stability.
4.1R protein stabilizes the spectrin-actin network (hori-
zontal interactions) and mediates the attachment of the
underlying cytoskeleton to the overlaying lipid bilayer
through vertical interactions with lipids as well as with
integral membrane proteins (protein band 3 and glycoph-
orins). Deficiency of 4.1R in red blood cells leads to the
assembly of an unstable cytoskeleton structure that mani-
fests itself by the loss of normal discoid morphology [3].
The 4.1R protein is expressed in many tissues [4,5] and in
specific neuronal populations, since it is a key element in
the regulation of central synapses [6,7]. An association
between a defect of 4.1R protein and the expression of
hyperkinetic disorders is hypothesised.
This study was approved by the Ethics Committee of the
"Istituto di Ricovero e Cura a Caratttere Scientifico"
(IRCCS) Santa Lucia, Rome, Italy. Informed consent was
obtained from all participants of the pedigrees.
We studied four patients from four different families
showing hyperkinetic movement disorders and acan-
thocytosis. Pedigrees are shown in Fig. 1. The patients pro-
vided us with their medical history, then underwent: a
neurological examination, psychiatric evaluation, neu-
ropsychological testing, electroencephalogram (EEG),
magnetic resonance imaging (MRI) brain scans, electro-
myography (EMG), electroneurography (NC), fundo-
scopic examination, cardiological assessment and gave
their informed consent to the collection of a blood sample
for molecular analysis. The following haematological tests
were studied in all patients: liver and thyroid functions,
serum electrolytes, serum vitamin A and E levels, cerulo-
plasmin, haptoglobin, creatine phosphokinase, cholester-
ols (total, HDL, LDL), triglycerides, and lipoproteins
(ApoA1, ApoB). Moreover, the expression of the Kell
blood group antigens was evaluated.
To check for the presence of expanded Huntington's dis-
ease (HD) alleles, the genetic analysis of the CAG distribu-
tion and adjacent polymorphic CCG repeats in the
Huntington gene was performed in all of the affected indi-
viduals, using previously reported methods [8,9]. All 73
exons plus flanking intronic sequence in the chorein gene
were screened for mutations by direct sequencing in four
probands with NA, as already described [10-12].
In order to perform membrane protein analysis the eryth-
rocyte membrane proteins were obtained from leukocyte
and platelet free red cells lysed with 5 mM Na2HpO4 pH
8.0 containing 0.1 mM PMSF. The electrophoretic analysis
of red blood cell (RBC) membrane proteins was per-
formed with 7.5% polyacrylamide gel electrophoresis in
sodium dodecyl sulfate (SDS-PAGE) [13]. The ghosts were
dissolved to a concentration of 1 mg protein/ml in SDS
sample buffer and 0.1 mg was loaded on gel. Crude spec-
trin was extracted from fresh ghosts in 0.1 mM Na/
Na2HPO4, 0.1 mM, 0.1 mM EDTA, 0.1 mM DTT, pH 8.0
at 0°C, and the content of spectrin dimers and tetramers
was determined on the supernatant by non-denaturing gel
electrophoresis (2% agarose in 4 mM Tris, 0.1 mM EDTA,
1% acetic acid buffer, pH 8.0). Patients, controls, and
molecular weight standards were always analysed on the
same gel and each sample was evaluated three times. Pro-
tein bands were stained with Coomassie Blue and quanti-
fied by densitometric analysis using a Fluor S Imager
(BIO-RAD) equipped with a MultiAnalyst software pack-
age. The content of 4.1 R protein was calculated as a per-
centage value of total membrane proteins according to
Lux SE and Palek J, 1995 [3]. The unpaired Student's t-test
was applied to compare data from patients (n. 4) and con-
trols (n. 21 healthy blood donors). Results are expressed
as means ± standard deviation (SD).
Case presentation
Patient IV:1 (RM23)
The proband – was a 19 year-old male, with no relevant
personal or family history showing mild involuntary oro-
facial movements and chorea in all four limbs. Psychomo-
tor assessment revealed no cognitive impairment. No
psychiatric manifestations were evident and the BeckPage 2 of 8
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comitant depression. EEG and brain MRI did not reveal
any pathological findings. Normal EMG and NC activity
was detected. Cardiomyopathy was excluded, fundo-
scopic examination showed no retinal degeneration, and
the expression of the Kell blood group antigens was nor-
mal. Haematological parameters were within normal
ranges, but a marked presence (95%) of abnormal shaped
erythrocytes known as acanthocytes were identified on
wet-film preparations. The patient's mother (age at exam-
ination: 37 years old) and sister did not show any neuro-
logical disorders, while a relevant presence of
acanthocytic erythrocytes was observed in peripheral
blood (35% and 39% respectively).
A decreased content of 4.1R protein was evident in the
patient, his mother, and his sister (Table 1). A marked
increase in spectrin dimers (35%, Reference Values <
Pedigrees of families RM13, RM15, RM16, and RM23Figu  1
Pedigrees of families RM13, RM15, RM16, and RM23. Black squares (males) and circles (females) indicate individuals affected 
with NA. Unaffected individuals are not shaded. Diagonal slashes represent deceased individuals. * Indicates individuals with 
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tion of spectrin dimers into tetramers is a critical interac-
tion for membrane structure and function [3]. The
percentage of spectrin dimers and tetramers in crude
extract reflects their relative distribution in the red cell
membrane in vivo. Increased percentage of spectrin dimers
is indicative of membrane fragility. The presence of a 4.1
R protein defect seems to give rise to the cytoskeleton
instability.
The diagnosis of HD was excluded by DNA molecular test-
ing and no disease mutations or single nucleotide poly-
morphisms (SNPs) were found in the ChAc gene.
Patient IV:1 (RM16)
The proband – was a 72 year-old diabetic woman. She
was hospitalized for two unexpected falls and the insidi-
ous onset of involuntary right arm movements. She devel-
oped a progression of continuous choreic-ballistic
movements in all four limbs associated with impaired gait
and orofaciolingual dyskinesias. Brain MRI scans showed
bilateral putaminal T2 hyper intensities, however EEG did
not reveal any pathological findings. The Beck Depression
Inventory Scale showed a moderate depressive status. The
EMG and NC results show axonal neuropathy. No cardio-
logical anomalies were evident, retinal degeneration was
absent, and the expression of the Kell blood group anti-
gens was normal. Haematological parameters were within
normal ranges, but numerous acanthocytes (77%) were
observed on the peripheral blood film preparations. The
patient's daughter showed no evidence of any neurode-
generative disorder, although acanthocytes were present
in her blood (31%). Exclusion of Wilson's disease and
non-Wilsonian hepatolenticular degeneration were pre-
sumed since hepatic copper content via liver biopsy was
within the normal range and due to the absence of liver
failure.
Analysis of RBC membrane proteins (Fig. 2 and Table 1)
showed a decreased content of 4.1R protein and protein
band 3 (data not shown), while the spectrin dimers (Fig.
3) were comparable to the control (11%, R.V. < 15%).
Therefore the 4.1R defect might affect vertical interactions
of skeletal attachment to membrane. Furthermore, the
patient's daughter showed the erythrocyte 4.1R defect
(Table 1) in spite of the absence of neurological signs.
The genetic analysis of the CAG distribution and adjacent
polymorphic CCG repeats in the HD gene was normal
and an absence of mutations in the ChAc gene was
reported.
Patient IV:3 (RM15)
The proband – was a 65 year-old man suffering from
hypertension. He reported a five-year history of depres-
sion and orofaciolingual involuntary movements. The
depression had been treated with tricyclic drugs and selec-
tive serotonine-uptake inhibitors. The neurological exam-
ination showed orofaciolingual diskinesias and right
distal limb dystonia. The Beck Depression Inventory
showed a moderate depressive status. EEG and brain MRI
did not reveal any pathological findings. The EMG and
NC recordings showed normal electrical activity. Cardio-
logical assessment was normal, retinal degeneration was
not present, and the expression of the Kell blood group
antigens was normal. Haematological parameters were
within normal ranges, although acanthocytes (32%) were
observed on the peripheral blood film preparations.
In this patient a decreased content of 4.1R protein was
observed (Fig. 2 and Table 1) and an increased amount of
spectrin dimers was measured (31%, R.V. < 15%) with an
impairment of the dimer self-association into tetramers.
A normal distribution of CAG and adjacent polymorphic
CCG repeats in the HD gene was reported and a genetic
search for ChAc gene mutations was negative.
Patient IV:6 (RM13)
The proband – was a 38 year-old man who was admitted
to hospital because of an isolated generalized tonic-clonic
seizure. He reported a four-year history of abnormal
involuntary upper limb movements of variable severity.
In his case history an acute episode of aggressive behav-
iour associated with delirium of persecution was also
reported. Neurological examination showed ballistic and
choreic movements of the arms (left > right) associated
with trunk dystonia and orofaciolingual diskinesias. Psy-
chiatric evaluation revealed anxiety, paranoia, depression,
obsessive behaviour, and marked emotional instability.
EEG and brain MRI did not reveal any pathological find-
ings. Axonal neuropathy was detected by EMG and NC
recordings. Cardiomyopathy was not found, fundoscopic
examination was normal, the same as the expression of
the Kell blood group antigens. Haematological parame-
ters were within normal ranges: however, acanthocytes
(85%) were observed on the peripheral blood film prepa-
rations.
Hypoxanthine-guanine phosphoribosyltransferase
(HPRT) enzyme activity in cells from cultured fibroblasts
was normal, excluding adult onset Lesch-Nyhan syn-
drome. The diagnosis of Gilles de la Tourette syndrome
was excluded by reason of onset after 18 years of age and
because of the absence of both multiple motor and one or
more vocal tics during the illness.
In this patient a decreased content of 4.1R protein was
observed (Fig. 2 and Table 1) and an increased amount ofPage 4 of 8
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impairment of the dimer self-association into tetramers.
The CAG units and adjacent polymorphic CCG repeats in
the HD gene were in the normal range and no disease-
causing mutation was found in the ChAc gene.
Table 1: Densitometric analysis of the erythrocyte 4.1R protein
Index of patients 4.1R (%)*
IV:1 (RM23) 3.8 ± 0.10
IV :1 (RM16) 2.8 ± 0.35
IV :3 (RM15) 3.3 ± 0.20
IV:6 (RM13) 3.6 ± 0.25
Relatives
IV:2 (RM23) 3.2 ± 0.30
III:5 (RM23) 3.1 ± 0.20
V:2 (RM16) 3.0 ± 0.30
Controls (n = 21) 4.41 ± 0.40^
* Patient values expressed as mean ± SD (n = 3)
^Reference values expressed as mean ± SD; from n.21 healthy blood donors. The 4.1R content was considered low when it was below the 
reference values.
Electrophoretic analyses (SDS-PAGE) of erythrocyte membrane proteins from patients (a = IV:6 RM13; c = IV:1 RM16; d = IV:3 RM15; e = IV:1 RM23) and controls (b, f)Figu e 2
Electrophoretic analyses (SDS-PAGE) of erythrocyte membrane proteins from patients (a = IV:6 RM13; c = IV:1 RM16; d = IV:3 
RM15; e = IV:1 RM23) and controls (b, f). MW = molecular weight standards.Page 5 of 8
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In the present study we report, for the first time, four cases
of NA showing choreic manifestations and acanthocytosis
with a novel alteration in the expression of the erythrocyte
membrane proteins: a 4.1R protein deficiency. Structural
modification of membrane proteins has rarely been
observed in NA; only a few cases of autosomal recessive
ChAc with abnormalities of the major integral membrane
protein band 3 have been reported [1,14-17]. Moreover,
ChAc has never been associated with 4.1R protein altera-
tions.
Acanthocytosis and abnormalities of erythrocyte mem-
brane proteins were revealed in all of the patients. The
erythrocyte membrane defect was due to a decreased con-
tent of 4.1R protein, a multifunctional skeletal protein
necessary for membrane stability and flexibility. The 4.1R
protein content was significantly lower in patients (3.40 ±
0.42) than in controls (4.41 ± 0.40, P < 0.0001), reflecting
weakened interactions of the cytoskeleton with the mem-
brane. In three patients the 4.1R protein defect involved
horizontal cytoskeleton interactions as shown by the
increased content of spectrin dimers and was indicative of
an impairment of the dimer self-association into tetram-
ers; in a patient with a decrease in protein band 3, the 4.1R
protein defect might impair the vertical interactions with
integral membrane proteins by affecting the skeletal
attachment to membrane.
The discovery of the new specific erythrocyte membrane
protein defect, an alteration of 4.1R protein, explains the
morphological changes in acanthocytosis and can provide
indications regarding the disease protein function. It
remains unknown whether genetic defect(s) could be
responsible for the two distinct phenotypes: acanthocyto-
sis and hyperkinesia. Interestingly, acanthocytosis and the
4.1R protein defect were also observed in other members
of the families showing no neurological symptoms. If
phenotypes observed in the families are due to genetic
defect(s), one possible explanation could be that unaf-
fected members might have a single mutation with a nor-
mal allele, i.e. they might be in a heterozygous state,
which leads to the phenotype of acanthocytosis only.
Mutations in both alleles or in combination with other
genetic modifier(s) would be required for the two distinct
phenotypes. Identification of genetic defect(s) in these
families would reveal the underlying mechanism(s) of
both phenotypes.
None of the patients presented the clinical or biochemical
abnormalities typically observed in either abetalipopro-
teinaemia or McLeod syndrome [1,2].
It is known that 4.1R protein is selectively expressed in
haematopoietic tissues and in specific neuronal popula-
tions [3]. Erythroid 4.1R protein is an 80-kDa skeletal pro-
tein required for structural organization and maintenance
of the RBC cytoskeleton [11]. 4.1R protein interacts with
spectrin and actin by strengthening the skeletal network
and stabilizes the spectrin-actin complexes through the
spectrin-actin binding (SAB) domain. Furthermore, the
4.1R N-terminal domain mediates the attachment of the
underlying cytoskeleton to the overlying lipid bilayer
through interactions with integral membrane proteins
such as band 3 and glycophorin C [3]. Abnormalities of
4.1R protein are associated with congenital RBC defects
leading to severe membrane fragmentation and hereditary
elliptocytosis [3,7].
Four genes encoding 4.1 proteins are known to be
expressed in the brain. The corresponding proteins are
known as 4.1R, 4.1G, 4.1B, and 4.1N. 4.1 proteins are
highly conserved and retain the same fundamental organ-
ization of domains [4,5,7,18]. High levels of 4.1R were
discretely localized in granule cells in the cerebellum and
dentate gyrus [19]. 4.1R protein is also selectively local-
ized in central neurons interacting with the intermediate
filament proteins of post-synaptic densities [7,20].
Recently, it has been postulated that 4.1 proteins play an
essential role in synaptic plasticity by delivering specific
subunits of glutamate AMPA receptors in central synapses
[6]. In line with this hypothesis 4.1R protein-null mice, as
well as the abnormal morphology and lowered mem-
brane stability of RBC, have specific deficits in move-
ments, coordination, and balance [19], therefore
highlighting a connection between 4.1R protein defi-
ciency and human neurodegenerative syndromes.
The present observation suggests a likely association
between a defect of 4.1R protein and the expression of
hyperkinetic disorders caused by a possible abnormal
glutamatergic transmission in the basal ganglia [21]. Pre-
Electrophoretic analyses of crude spectrin extracts from patients (a = IV:1 RM23; b = IV:1 RM16) and control (c)Figu e 3
Electrophoretic analyses of crude spectrin extracts from 
patients (a = IV:1 RM23; b = IV:1 RM16) and control (c).Page 6 of 8
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receptor-mediated transmission, by facilitating glutamate
release from corticostriatal terminals or AMPA receptor
currents with ampakines [22,23], might prove beneficial
in treating motor disorders associated with 4.1R altera-
tions.
Our sequence analyses did not show any disease-associ-
ated mutations or polymorphisms in the ChAc. If the
decreased expression of 4.1R protein is due to genetic
defect(s), two possible explanations might be considered
for the results of our genetic study. Firstly, there might be
other genetic defect(s) in the ChAc gene including the reg-
ulatory region, which was not examined in our analysis.
Secondly, there might be further as yet unknown genetic
defect(s) or further locus heterogeneity in NA. However,
previous papers have revealed little evidence of further
locus heterogeneity in neuroacanthocytosis [10].
We have demonstrated that expression of 4.1R protein in
erythrocytes is decreased in patients with atypical neuroa-
canthocytosis, but there is no evidence of decreased
expression of the protein in the brain because we did not
examine post-mortem brains of patients. Analyses of
4.1R-deficient mice showed lower membrane stability of
RBC, movement abnormalities, abnormal morphology
and decreased expression of the protein in the brain
nucleus/tissues including granule cells and dentate gyrus
[24]. The functional effect(s) of decreased expression of
4.1R protein in the brain remains unknown. A previous
study revealed that 4.1R proteins play an essential role in
synaptic plasticity by delivering specific subunits of gluta-
mate AMPA receptors into central synapses [25]. The
altered metabolism of glutamate AMPA might lead to dys-
function of neurotransmission in the basal ganglia and
hyperkinetic movements in neuroacanthocytosis.
It also remains unknown whether the expression pattern
of protein in erythrocytes might reflect their expression
patterns in the brain. An investigation into the expression
of alpha-synuclein in lymphocytes from PARK1-patients
demonstrated that decreased expression of alpha-synu-
clein correlates with the severity of the clinical phenotype
[26], suggesting that expression patterns of protein in
peripheral tissue might not be independent from those in
the central nervous system. Investigation of expression of
4.1R protein in post-mortem brains of patients with neu-
roacanthocytosis is a prerequisite for validation of
decreased expression of 4.1R protein and understanding
biological mechanism(s) for hyperkinesia in NA.
In conclusion, our study demonstrates decreased expres-
sion of 4.1R protein in the erythrocytes, which might
reflect decreased expression of this protein in the brain
resulting in hyperkinetic movements in neuroacanthocy-
tosis.
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